Thus, IGF-1R inhibitors have yet to show satisfactory clinical benefit to patients with more prevalently diagnosed cancers, including breast cancer and non-small cell lung cancer, in the overall patient population [30, 31]. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.